argumentA line of reasoning from premises to a conclusion. Like a claim, it belongs to no one who makes it.constitution →

Some LDL-lowering interventions failed to deliver proportional benefit

againstThis argument, if it holds, weighs against the claim.constitution →Non-statin LDL-lowering therapies reduce cardiovascular events proportionally to the LDL reduction achieved

The argument

If linked claim, then LDL reduction alone does not guarantee proportional event reduction across every non-statin intervention, so the claim holds only once such cases are accounted for by mechanism or off-target effects.

Does it work?

Does it follow?: slight even if the premises holdEven if the premises are true, they make the conclusion only a little more likely.constitution →
Do the premises hold?: 1 verified

Suppose some LDL-lowering interventions failed to reduce events. That defeats the literal universal wording of the claim. It bears only slightly on proportionality for on-target lowering, because each failure has an identified explanation outside LDL: off-target toxicity, too little added lowering, or a different mechanism.

Premises

VerifiedThe evidence, examined directly, establishes the claim.constitution →Some interventions that lower LDL cholesterol failed to reduce cardiovascular events

Where it is made

Passages where sources make, criticize or mention this argument. They record where it appears, not how strong it is, and none has precedence over another.

No source is recorded as making it.

Earlier ratings

Jul 19, 2026
Granting that some LDL-lowering interventions failed to reduce events, the inference correctly defeats the unrestricted universal reading: LDL reduction alone does not guarantee proportional benefit across every agent. Its force stops there. Because the documented failures have specific off-target (torcetrapib) or insufficient-lowering (niacin, the earlier CETP inhibitors) explanations, and anacetrapib later reduced events, the argument establishes a scope limitation without undermining the proportionality of receptor-mediated LDL lowering. It is why the parent claim sits at supported rather than verified, not a case for contradicted.
Jul 19, 2026
Granting that some LDL-lowering interventions failed to reduce events, the inference correctly rules out the unrestricted universal reading: LDL reduction alone does not guarantee proportional benefit across every agent. Its force stops there. Because the documented failures have specific off-target (torcetrapib) or insufficient-lowering (niacin, the earlier CETP inhibitors) explanations, and anacetrapib later reduced events, the argument establishes a scope limitation without undermining the proportionality of receptor-mediated LDL lowering. It is the reason the parent claim sits at "supported" rather than "verified," not a case for "contradicted."